We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...

The US Food and Drug Administration has accepted Sobi’s supplemental biologics licence application for Gamifant ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

We expect investors to focus on the sales performance of ADMA Biologics’ ADMA portfolio of marketed products and other ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...

Zacks Investment Research Image Source: Zacks Investment Research ADMA’s supplemental biologics license applications (sBLAs) for both Asceniv and Bivigam were approved by the FDA last year.